Treatment of Blastocystis Hominis infection ameliorates Hashimoto’s thyroiditis: Relation to IL-17

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909495111649

Enrollment

Registered

2019-09-05

Start date

2017-12-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

Hashimotos thyroiditis with Blastocystis Hominis infection

Healthy subjects without HT and negative for BH

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with Hashimotos thyroiditis - Patients with Hashimotos thyroiditis and Blastocystis Hominis infection

Exclusion criteria

Exclusion criteria: - Parasitic infections (other than Blastocystis hominis). - Autoimmune diseases (Other than Hashimoto’s thyroiditis). - Diabetes mellitus. - Cardiovascular diseases. - Malignancy & chronic inflammatory diseases. - Pregnant or breastfeeding women. - Patients receiving medications (including drugs affecting thyroid function).

Design outcomes

Primary

Measure	Time frame
Effect on serum IL-17	—

Secondary

Measure	Time frame
effect on thyroid profile	—

Countries

Egypt

Contacts

Public ContactHanaa Abdelhalem

Researcher Alexandria University

hanaaabdalbasit@yahoo.com+201014048787

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026